22 results on '"Rodon Ahnert, Jordi"'
Search Results
2. Phase 1/2 study of FOG-001, a first-in-class direct β-catenin:TCF inhibitor, in patients with colorectal cancer, hepatocellular carcinoma, and other locally advanced or metastatic solid tumors.
3. PRECISION 1: A phase 2, multicenter, open-label basket trial of nab -sirolimus for malignant solid tumors harboring pathogenic inactivating alterations in TSC1 and TSC2.
4. Clinical characterization and therapeutic outcomes of patients (pts) with colorectal cancer (CRC) harboring somatic BRCA1/2 mutations.
5. PRECISION 1: A phase 2, multicenter, open-label basket trial of nab -sirolimus for malignant solid tumors harboring pathogenic inactivating alterations in TSC1 and TSC2.
6. Phase 2, multicenter, open-label basket trial of nab -sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I).
7. A phase 1, open-label, first-in-human study of TAS2940 in patients with advanced solid tumors.
8. A phase 1 first-in-human clinical trial of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, in advanced solid tumors.
9. Clinical trial deserts: US urban vs rural patient enrollment among patients with advanced cancer in phase 1 clinical trials at a major cancer center.
10. The effect of LNS8801 alone and in combination with pembrolizumab in patients with metastatic uveal melanoma.
11. SKB264 (TROP2-ADC) for the treatment of patients with advanced NSCLC: Efficacy and safety data from a phase 2 study.
12. Molecular landscape and survival outcomes on early phase clinical trials in sporadic young onset colorectal cancer.
13. Dose optimization of novel BRAF inhibitor FORE8394 based on PK and efficacy results.
14. A phase 2 study of the WEE1 inhibitor AZD1775 in SETD2 -deficient advanced solid tumor malignancies.
15. Intrapatient comparative efficacy of selective RET inhibitors using growth modulation index in patients with RET aberrant cancers.
16. Safety and efficacy of the novel BRAF inhibitor FORE8394 in patients with advanced solid and CNS tumors: Results from a phase 1/2a study.
17. Lefitolimod (TLR agonist) and ipilimumab in patients with advanced solid tumors: A phase I trial.
18. First-in-human, phase 1a dose finding of LVGN6051 CD137/4-1BB agonistic antibody with or without pembrolizumab in patients with advanced solid tumors.
19. Baseline symptom, health status, and health utilities in patients in early-phase clinical trials combining immune checkpoint blockade with other anticancer therapies.
20. Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I).
21. Landscape of BRAF mutation classes in intrahepatic cholangiocarcinoma.
22. What It Takes to Improve a First-Generation Inhibitor to a Second- or Third-Generation Small Molecule.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.